Clinical Trial: SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047443) titled 'SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression' on June 23.

Brief Summary: To find the optimal dose of carboplatin combined with SHR-A1811 in her2-expressed metastatic breast cancer

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: SHR- A1811

HER2 ADC

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Anhui Provincial Cancer Hospital

Information provided by (Responsible Party): Yue-Yin Pan, Anhui Provincial Cancer Hospital

Published by HT Digital Content Services with permission from Health Daily Digest....